Lilly Foundayo Clears Heart Safety for Diabetes Filing; Cochrane Calls Amyloid Drugs 'Trivial'

Lilly's oral GLP-1 Foundayo clears a major cardiovascular safety hurdle in diabetes, and the company says a diabetes filing is coming by end of Q2. But the FDA wants a closer look at the liver.

A Cochrane review just called anti-amyloid Alzheimer's drugs "trivial," Roche is going back to Phase 3 for Elevidys after Europe said no, and half a billion dollars is about to hit the obesity IPO market.

Welcome to The Pharma Closeout for Thursday, April 16th, 2026. I'm Alex Mercer.

And I'm Maya Patel. Let's get into it. ### [TOP STORY] — Lilly Foundayo ACHIEVE-4 Results & FDA Liver Risk Request

Lilly reported ACHIEVE-4 results this morning — the longest Phase 3 study of Foundayo, their oral GLP-1, orforglipron. Headline numbers: the drug met its primary non-inferiority MACE-4 endpoint against long-acting insulin with a hazard ratio of 0.84, confidence interval 0.59 to 1.20. On top of that, Foundayo showed superior A1C and weight reductions versus insulin over roughly two years of follow-up.

The MACE-4 composite is worth unpacking briefly — it includes hospitalization for unstable angina on top of cardiovascular death, MI, and stroke. That's a harder bar than MACE-3. With the upper bound of the confidence interval well below 1.3, there's no cardiovascular safety concern here. And that 0.84 point estimate hints at potential benefit, though the trial wasn't powered for an outcomes superiority claim.

Lilly moved fast on the commercial framing. Per the company, they plan to submit Foundayo to US regulators for type 2 diabetes by end of Q2. The drug already cleared the FDA for obesity on April 1st — which means this filing would create a dual-indication oral GLP-1. That's a fundamentally different competitive proposition against Novo Nordisk's injectable-heavy portfolio.

But there's a second thread that deserves equal weight. The FDA's approval letter for the obesity indication included a request for Lilly to evaluate Foundayo's liver risk. Lilly has stated no liver or heart signals appeared across any of their large late-stage trials. Still — the FDA making that request in the approval letter itself, publicly, creates a cloud. Particularly for payers building formulary models around this drug right now.

And that's where the competitive dynamics sharpen. Clean cardiovascular data swings the door open for the diabetes label. But a liver safety flag — even framed as a post-marketing evaluation — gives payers and competitors something concrete to cite.

I'd push back on calling it a competitive weapon. A post-marketing evaluation is not a clinical hold. There is no signal in the data today. The risk here is perceptual — if the request shapes formulary positioning before Lilly has the chance to report the evaluation out, the damage is done regardless of the results.

Fair point — the data don't support a liver problem right now. But in the Lilly-Novo marketing war, perception moves at the speed of a sales call, not a clinical data package. Label breadth and safety narratives will shape the next twelve months as much as raw efficacy.

And here's the wider implication. If the FDA is establishing a precedent of requesting hepatic evaluations for oral GLP-1s as a class, that changes the regulatory calculus for every company behind Lilly in this mechanism — and there are several lined up.

Shifting to the deal side. Daiichi Sankyo is selling its consumer health unit to Suntory for 246.5 billion yen — roughly 1.5 billion dollars. OTC medicines, skincare, oral care, nutritional products — all going out the door. That frees Daiichi to go all-in on its oncology and ADC franchise, particularly the Enhertu partnership with AstraZeneca. Separately, Lilly closed the acquisition of CrossBridge Bio for up to 300 million, adding dual-payload ADC technology to what's becoming a deliberate antibody-drug conjugate platform build.

Roche, meanwhile, announced a new Phase 3 for Elevidys, the DMD gene therapy partnered with Sarepta. This follows the EU regulator's rejection last year. A new pivotal trial means years of additional investment and delay for a therapy that's already approved in the US. Roche clearly isn't abandoning Europe on gene therapy — but running a second Phase 3 to satisfy a different regulatory bar is expensive, and the read-through for other gene therapy programs eyeing EU submissions is sobering.

On the capital markets side — Revolution Medicines priced a 2 billion dollar raise after their pancreatic cancer drug nearly doubled survival in a Phase 3 that one analyst called a "game changer." And Obsidian Therapeutics completed a reverse merger with Galera, securing a 350 million dollar PIPE to advance TIL cell therapy. Combined company trades under ticker OBX.

Then there's Kailera Therapeutics, which priced its IPO this week targeting up to 533 million dollars at 14 to 16 dollars per share. Shares are expected to begin trading tomorrow. A pre-revenue obesity biotech raising half a billion in this tape tells you the capital allocation thesis for GLP-1 is far from exhausted — even with Lilly and Novo dominating the clinical landscape.

On the regulatory side — the most consequential story today isn't an FDA action. It's a Cochrane systematic review published this morning concluding that anti-amyloid Alzheimer's drugs produce effects that are, in the reviewers' language, "absent or trivial" on cognitive decline and dementia severity over 18 months. Improvements in functional ability were described as "small at best."

The backlash from the Alzheimer's research community and the companies behind these therapies was immediate — and loud.

It will stay loud. Cochrane carries weight with payers and HTA bodies that individual trial publications simply don't. But where this gets methodologically contested is whether the minimal clinically important difference cutoffs the reviewers applied are appropriate for patients at the earliest symptomatic stages — before neurodegeneration has compounded. That's where the field genuinely splits, and this review does not resolve it.

The commercial read-through is blunt. If European HTA bodies or US payers lean on a Cochrane-level dismissal to justify tighter coverage, multi-billion-dollar Alzheimer's franchises at Eisai, Biogen, and Lilly face headwinds that no Phase 3 subgroup analysis can easily counter. This will resurface in every reimbursement conversation for the next year.

Also worth noting on the regulatory side — the FDA is signaling movement on easing restrictions for compounded peptides, with an advisory committee set to discuss reclassification. And Erica Schwartz, former deputy surgeon general, has been selected as the next CDC director pending Senate confirmation.

Meanwhile, former FDA oncology chief Richard Pazdur warned this week about what he called a political "breach" at the agency. Between the peptide debate, a new CDC director nominee, and increasing political pressure on FDA leadership, the institutional environment is shifting — and that matters for every company navigating a pending application or a launch window right now.

Looking ahead — Kailera shares are expected to begin trading tomorrow. That's the market's first live verdict on a pure-play GLP-1 obesity IPO at this scale in 2026. And UnitedHealth reports Q1 earnings on April 21st — membership is expected to contract to between 46.9 and 47.5 million, down from 49.8 million, with the DOJ probe still unresolved. That number sets the tone for managed care through the second half of the year.

Watch the Cochrane fallout over the next few days — expect response publications and company rebuttals. That methodological debate will shape reimbursement conversations well beyond this week.

And the Foundayo diabetes filing clock is officially running — Lilly targeting end of Q2. The liver safety request becomes the fine print every payer reads before the efficacy headline.

That's your Pharma Closeout for Thursday. Foundayo clearing the cardiovascular bar, a Cochrane review reigniting the amyloid debate at the worst possible time, Daiichi Sankyo going all-in on oncology, and Kailera opening for trading tomorrow in what could be the biggest obesity IPO test of the year. If this briefing saves you time, subscribe wherever you listen and drop us a rating — we're back tomorrow with the Kailera open and whatever else this industry throws at us.

Have a great Thursday evening. See you tomorrow.